Sanofi said HHS has agreed to provide $43.2 million in funding forthe phase II development of an inactivated Zika vaccine. The French pharmaceutical company’s vaccines global business unit, Sanofi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback